According to GlobalData, the worldwide thrombectomy device market was worth $2.96 billion in 2024 and is set to register a ...

Inari’s expertise combined with Stryker’s existing distribution and logistics network could boost volume and procedure ...

A minimally invasive procedure finds and removes clots from the body. Credit: Vitalii Vodolazskyi via Shutterstock. Major medical device manufacturing company Stryker has announced the total ...

Stryker has completed its $4.9 billion acquisition of Inari Medical, a company specializing in venous thromboembolism ...

花旗更新后的财务模型考虑了Inari对Stryker业绩的预期贡献。预计Inari在2025年约10个月期间将产生5.9亿美元的收入。尽管预计Inari将使Stryker的营业利润率降低0-20基点，但预计也将为每股收益（EPS）增加0.20至0.30美元。

Following a hefty raise by Beta Bionics last month, Kestra’s IPO means medtech has enjoyed a strong 2025 start for listings.

Citi resumed coverage of Stryker (SYK) with a Buy rating and $450 price target following the close of the Inari acquisition tryker has built a ...

Analysts expect Inari Medical to post earnings of ($0.01) per share and revenue of $160.70 million for the quarter. Inari Medical Stock Up 0.1 % Shares of NASDAQ:NARI opened at $79.97 on Monday.

The wearable cardiac monitor and defibrillator developer Kestra Medical Technologies aims to raise about $154 million by ...

If you are looking for growth stocks, the medical device sector is a promising one to start your search. The post Growth ...